DISEASE INDICATIONS: Urothelial Carcinoma, Breast Cancer, Lung Cancer
MANUFACTURER: Roche Registration Limited
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA)
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Tecentriq (Atezolizumab) is an immunotherapy drug used to treat advanced non-small cell lung cancer and urothelial carcinoma (bladder cancer). By blocking protein PD-L1, it helps the immune system attack and destroy cancer cells.